7 completed, 3 active not recruiting, 1 terminated, 1 withdrawn. 12 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 7, Active not recruiting 3, Terminated 1, Withdrawn 1 |
| Phase 1 | 3 | Completed 3 |
Follow Antibody-mediated Rejection: new trials by email Literature Review of Antibody-mediated Rejection trials Research Report on Antibody-mediated Rejection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Daratumumab Followed by Telitacicept for the Treatment of ABMR After Kidney Transplantation-A Phase IIa Clinical Trial Methylprednisolone (MP), Daratumumab, Telitacicept - Antibody-mediated Rejection, Antibody-Mediated Rejection (AMR) | Phase 2 | Active not recruiting | First Affiliated Hospital, Sun Yat-Sen University | 20 | 2026-06-20 | 2026-10-29 |
| Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation ALXN2030, Placebo - Antibody-Mediated Rejection, Kidney Transplantation | Phase 2 | Active not recruiting | Alexion Pharmaceuticals, Inc. | 47 | 2025-03-07 | 2026-08-11 |
| A Study to Evaluate the Safety and Tolerability of Efgartigimod PH20 SC Given by Prefilled Syringe in Kidney Transplant Recipients With Antibody-Mediated Rejection (AMR) Efgartigimod PH20 SC - prefilled syringe, Placebo PH20 SC - prefilled syringe - Antibody-mediated Rejection | Phase 2 | Active not recruiting | argenx | 33 | 2024-08-30 | 2026-07-02 |
| Felzartamab in Late Antibody-Mediated Rejection Felzartamab, Placebo - Antibody-mediated Rejection | Phase 2 | Completed | Farsad Eskandary | 22 | 2021-10-06 | 2024-04-18 |
| Desensitization in Kidney Allograft Using Daratumumab Daratumumab dose escalation, Daratumumab full dose - Allosensitization, Kidney Transplant Rejection | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 21 | 2020-02-18 | 2024-03-19 |
| Belatacept Pilot Study in Lung Transplantation Immunosuppression in Lung Transplantation Belatacept, Tacrolimus, ATG - Lung Transplant Rejection, Antibody-mediated Rejection | Phase 2 | Completed | Washington University School of Medicine | 27 | 2019-12-17 | 2022-11-25 |
| Lung Transplant Plasmapheresis/Belatacept/Carfilzomib for Antibody Mediated Rejection and Desensitization Belatacept, Carfilzomib - Lung Transplant Rejection, Antibody-mediated Rejection | Phase 2 | Withdrawn | Duke University | 2019-05-01 | 2019-05-02 | |
| Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Clazakizumab - Kidney Failure, Chronic, End-Stage Renal Disease | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 20 | 2018-02-27 | 2026-10-30 |
| Clazakizumab for Chronic and Active Antibody Mediated Rejection Post-Kidney Transplant Clazakizumab - Antibody-mediated Rejection, Kidney Transplant; Complications | Phase 1 / Phase 2 | Completed | Stanley Jordan, MD | 10 | 2018-02-21 | 2025-05-06 |
| A Pilot Trial of Clazakizumab in Late ABMR Clazakizumab / Clazakizumab, Placebo / Clazakizumab - Antibody-mediated Rejection | Phase 2 | Completed | Medical University of Vienna | 20 | 2018-01-16 | 2020-09-09 |
| Bortezomib in Late Antibody-mediated Kidney Transplant Rejection Bortezomib, Placebo - Late Rejection of Renal Transplant, Antibody-mediated Rejection | Phase 2 | Completed | Medical University of Vienna | 44 | 2013-12-01 | 2017-03-23 |
| Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation Eculizumab, Immunoglobulin, Plasmapheresis - Antibody-mediated Rejection, Humoral Rejection | Phase 2 | Terminated | Brigham and Women's Hospital | 11 | 2013-11-01 | 2017-09-21 |
Rejection, Psychology (2) · Kidney Failure, Chronic (1)
Behavior (2) · Social Behavior (2) · Chronic Disease (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1) · Urogenital Diseases (1) · Urologic Diseases (1)
clazakizumab (3) · Abatacept (2) · Methylprednisolone (2) · Saline Solution (2) · Bortezomib (1) · Immunoglobulins (1) · Immunoglobulins, Intravenous (1) · Methylprednisolone Hemisuccinate (1) · Mycophenolic Acid (1) · Plasmapheresis (1) · Prednisone (1) · Sodium Chloride (1) · Tacrolimus (1) · carfilzomib (1) · daratumumab (1)
Medical University of Vienna (2) · Stanley Jordan, MD (2) · Alexion Pharmaceuticals, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Brigham and Women's Hospital (1) · Duke University (1) · Farsad Eskandary (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Washington University School of Medicine (1) · argenx (1)
United States (6) · Austria (4) · Germany (3) · Canada (2) · China (2) · France (2) · Spain (2) · Belgium (1) · Brazil (1) · Czechia (1) · South Korea (1) · Taiwan (1) · United Kingdom (1)
Stanley Jordan, MD (2) · Anil K Chandraker, MD (1) · Bernd Jilma, MD (1) · Laurie Snyder (1) · Marie Matignon, MD (1) · Ramsey R Hachem, MD (1)
PMID 24708575, PMID 26281144, PMID 30635033, PMID 31530561, PMID 34153143, PMID 35395951, PMID 36382130, PMID 37322595, PMID 37899481, PMID 38804514, PMID 39134120, PMID 39780312, PMID 40444214, PMID 42855714
2017 (1), 2023 (1)